CA2462758A1 - Indicateur de diagnostic de la fonction thymique - Google Patents

Indicateur de diagnostic de la fonction thymique Download PDF

Info

Publication number
CA2462758A1
CA2462758A1 CA002462758A CA2462758A CA2462758A1 CA 2462758 A1 CA2462758 A1 CA 2462758A1 CA 002462758 A CA002462758 A CA 002462758A CA 2462758 A CA2462758 A CA 2462758A CA 2462758 A1 CA2462758 A1 CA 2462758A1
Authority
CA
Canada
Prior art keywords
use according
patient
thymus
cells
sex steroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002462758A
Other languages
English (en)
Inventor
Richard Boyd
Ann Patricia Chidgey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Norwood Immunology Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR0745A external-priority patent/AUPR074500A0/en
Priority claimed from US09/755,965 external-priority patent/US20010046486A1/en
Application filed by Individual filed Critical Individual
Publication of CA2462758A1 publication Critical patent/CA2462758A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5759—Thymosin or related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Prostheses (AREA)

Abstract

La présente invention concerne un procédé permettant de déterminer si le système immunitaire d'un patient peut être modifié par stimulation de la fonction thymique. Dans un mode de réalisation préféré, des stéroïdes sexuels sont prélevés par ablation sur le patient et la production résultante de facteurs thymiques est contrôlée. On surveille en particulier le taux de ces facteurs dans le courant sanguin du patient. Dans un autre mode de réalisation, le taux de nouveaux lymphocytes T est contrôlé. Une réponse rapide, par exemple au cours des heures ou des jours suivant l'ablation, indique que le thymus du patient présente une disposition à la régénération par ablation de stéroïdes sexuels.
CA002462758A 2000-10-13 2001-10-12 Indicateur de diagnostic de la fonction thymique Abandoned CA2462758A1 (fr)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US79530200A 2000-10-13 2000-10-13
US79528600A 2000-10-13 2000-10-13
AUPR0745A AUPR074500A0 (en) 2000-10-13 2000-10-13 Treatment of t cell disorders
US09/795,302 2000-10-13
US09/795,286 2000-10-13
AUPR0745 2000-10-13
US75598301A 2001-01-05 2001-01-05
US75564601A 2001-01-05 2001-01-05
US09/755,983 2001-01-05
US09/755,965 US20010046486A1 (en) 2000-04-17 2001-01-05 Stimulation of thymus for vaccination development
US09/755,965 2001-01-05
US09/755,646 2001-01-05
US75891001A 2001-01-10 2001-01-10
US09/758,910 2001-01-10
US09/885,268 2001-08-01
US09/885,268 US20030017153A1 (en) 2000-10-13 2001-08-01 Diagnostic indicator of thymic function
PCT/IB2001/002351 WO2002030256A2 (fr) 2000-10-13 2001-10-12 Indicateur de diagnostic de la fonction thymique

Publications (1)

Publication Number Publication Date
CA2462758A1 true CA2462758A1 (fr) 2002-04-18

Family

ID=27570137

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002462758A Abandoned CA2462758A1 (fr) 2000-10-13 2001-10-12 Indicateur de diagnostic de la fonction thymique

Country Status (8)

Country Link
EP (1) EP1365790A4 (fr)
JP (1) JP2004523730A (fr)
CN (1) CN1516597A (fr)
AU (1) AU2002218450A1 (fr)
CA (1) CA2462758A1 (fr)
IL (1) IL155412A0 (fr)
NZ (1) NZ525826A (fr)
WO (1) WO2002030256A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008057479A1 (de) 2008-11-14 2010-05-20 Bernhard, Stefan, Dr. Vorrichtung und Verfahren zur Stärkung des Immunsystems durch Langzeitstimulation der Thymusdrüse

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102772783A (zh) * 2007-01-25 2012-11-14 中国生化制药工业协会 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途
ES2331499B1 (es) * 2007-08-02 2010-10-14 Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud En Sevilla (Fund.Sevilla) Cebadores, procedimiento y conjunto de utiles para la determinacion d e la funcionalidad del timo humano.
US20090136946A1 (en) * 2007-11-27 2009-05-28 Mark Carle Connelly Automated Enumeration and Characterization of Circulating Melanoma Cells in Blood
RU2529625C2 (ru) 2010-01-19 2014-09-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Устройства и системы для генерации высокочастотных ударных волн и способы их использования
AR087170A1 (es) 2011-07-15 2014-02-26 Univ Texas Aparato para generar ondas de choque terapeuticas y sus aplicaciones
CN103173534B (zh) * 2012-11-20 2014-08-06 无锡联合利康临床检验所有限公司 一种定量检测TRECs基因的实时荧光定量PCR试剂盒及应用
US10835767B2 (en) 2013-03-08 2020-11-17 Board Of Regents, The University Of Texas System Rapid pulse electrohydraulic (EH) shockwave generator apparatus and methods for medical and cosmetic treatments
WO2016183307A1 (fr) * 2015-05-12 2016-11-17 Soliton, Inc. Procédés de traitement de la cellulite et du tissu adipeux sous-cutané
TWI742110B (zh) 2016-07-21 2021-10-11 美商席利通公司 具備改良電極壽命之快速脈波電動液壓脈衝產生裝置及使用該裝置生成壓縮聲波之方法
WO2018152460A1 (fr) 2017-02-19 2018-08-23 Soliton, Inc. Rupture optique sélective induite par laser dans un milieu biologique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP977899A0 (en) * 1999-04-15 1999-05-13 Monash University Improvement of t cell mediated immunity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008057479A1 (de) 2008-11-14 2010-05-20 Bernhard, Stefan, Dr. Vorrichtung und Verfahren zur Stärkung des Immunsystems durch Langzeitstimulation der Thymusdrüse

Also Published As

Publication number Publication date
EP1365790A2 (fr) 2003-12-03
NZ525826A (en) 2006-06-30
CN1516597A (zh) 2004-07-28
WO2002030256A9 (fr) 2003-09-12
EP1365790A4 (fr) 2006-05-31
WO2002030256A2 (fr) 2002-04-18
IL155412A0 (en) 2003-11-23
WO2002030256A3 (fr) 2002-07-25
AU2002218450A1 (en) 2002-04-22
JP2004523730A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
US20030017153A1 (en) Diagnostic indicator of thymic function
CA2462758A1 (fr) Indicateur de diagnostic de la fonction thymique
US20020136704A1 (en) Diagnostic indicator of thymic function
EP1363703A2 (fr) Prevention de maladies par reactivation du thymus
US20020119128A1 (en) Graft acceptance through manipulation of thymic regeneration
CA2462073A1 (fr) Therapie genique aux cellules souches hematopoietiques
AU2002216323C1 (en) Disease prevention by reactivation of the thymus
AU2002225245B2 (en) Improvement of graft acceptance through manipulation of thymic regeneration
CA2462671A1 (fr) Normalisation de la reactivite de lymphocytes t deficients par la manipulation de la regeneration thymique
AU2002216320C1 (en) Hematopoietic stem cell gene therapy
AU2007202613A1 (en) Diagnostic indicator of thymic function
CA2462027A1 (fr) Stimulation du thymus pour ameliorer une vaccination
US20020086003A1 (en) Stimulation of thymus for vaccination development
US20040037817A1 (en) Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20040037816A1 (en) Graft acceptance through manipulation of thymic regeneration
ZA200303684B (en) Stimulation of thymus for vaccination development
US20020110540A1 (en) Disease prevention by reactivation of the thymus
AU2002216323A1 (en) Disease prevention by reactivation of the thymus
AU2007202609A1 (en) Stimulation of thymus for vaccination development
AU2002225245A1 (en) Improvement of graft acceptance through manipulation of thymic regeneration
AU2007202610A1 (en) Normalization of defective T cell responsiveness through manipulation of thymic regeneration
KR20030076572A (ko) 흉선 기능의 진단 인디케이터
ZA200303686B (en) Disease prevention by reactivation of the thymus.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued